Sonnet BioTherapeutics Holdings, Inc. Common Stock
Symbol: SONN (NASDAQ)
3.50
▼ (-6.91%) -0.260
Company Description:
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Key Stats
- Today's Open: $3.68
- Today's High: $4.05
- Today's Low: $3.345
- Today's Volume: 609.46K
- Yesterday Close: $3.76
- Yesterday High: $4.29
- Yesterday Low: $3.49
- Yesterday Volume: 1.45M
- Last Min Volume: 1.40K
- Last Min High: $3.5
- Last Min Low: $3.5
- Last Min VWAP: $3.5
Company Profile
- Name: Sonnet BioTherapeutics Holdings, Inc. Common Stock
- Website: https://www.sonnetbio.com
- Listed Date: 2020-04-01
- Location: PRINCETON, NJ
- Market Status: Active
- CIK Number: 0001106838
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $22.18M
- Round Lot: 100
- Outstanding Shares: 6.26M
- Asset Type: CS
RECENT FILINGS FOR SONN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-13 | 10-Q | View |
| 2025-08-01 | 8-K | View |
| 2025-07-25 | SCHEDULE 13G | View |
| 2025-07-25 | 8-K | View |
| 2025-07-18 | 8-K | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-14 | 425 | View |
| 2025-07-14 | 8-K | View |
| 2025-07-02 | 8-K | View |
| 2025-06-02 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-04-04 | 8-K | View |
Latest News on SONN